Výsledky vyhledávání - "Charles Bisgaier"

Akademický článek

Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins

Autor: Shucun Qin, Koichi Kawano, Can Bruce, Min Lin, Charles Bisgaier, Alan R. Tall, Xian-cheng Jiang

Publikováno v: Journal of Lipid Research, Vol 41, Iss 2, Pp 269-276 (2000)

Phospholipid transfer protein gene knock-out (Pltp KO) mice have defective transfer of very low density lipoprotein (VLDL) phospholipids into high density lipoprotein (HDL) and markedly decreased HDL levels (Jiang et al. 1999. J. Clin. Invest. 103: 9

Externí odkaz: https://doaj.org/article/4a565001cd124579aca542b316e26698

Zobrazit plný text záznamu

Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)

Autor: Robert A. Hegele, Norman E. Lepor, Evan A. Stein, Rebecca Bakker-Arkema, Liz Masson, Charles Bisgaier, Ronen Durst, Lee Golden, John J.P. Kastelein, Daniel Gaudet

Publikováno v: American journal of cardiology, 124(12), 1876-1880. Elsevier Inc.

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated plasma low-density lipoprotein-cholesterol (LDL-C), and premature atherosclerotic cardiovascular disease. Depending on residual LDL receptor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b4ab6a069c802800e696a94d207ed36
https://pure.amc.nl/en/publications/usefulness-of-gemcabene-in-homozygous-familial-hypercholesterolemia-from-cobalt1(84022de0-ccab-4671-9fa3-51e8b20845c7).html

Zobrazit plný text záznamu

Abstract 23082: Gemcabene Add-On Therapy to High- and Moderate-Intensity Statin Stratums in Hypercholesterolemic Subjects (ROYAL-1, a Phase 2b Study)

Autor: Juan Frias, John Kastelein, Rebecca Bakker-Arkema, Liz Masson, Lee Golden, Charles Bisgaier, Evan Stein

Publikováno v: Circulation. 136

Introduction: Recent large cardiovascular event outcome trials with ezetimibe and a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor added to statins demonstrated benefit from additional LDL-C reduction. Despite availability of approve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a384814dffeaf0aca52464bdbd652091
https://doi.org/10.1161/circ.136.suppl_1.23082

Zobrazit plný text záznamu

PON1 and oxidative stress in human sepsis and an animal model of sepsis

Autor: Dragomir, Draganov, John, Teiber, Catherine, Watson, Charles, Bisgaier, Jean, Nemzek, Daniel, Remick, Theodore, Standiford, Bert, La Du

Publikováno v: Advances in experimental medicine and biology. 660

Sepsis is the leading cause of death in critically ill patients. The pathophysiological mechanisms implicated in the development of sepsis and organ failure are complex and involve activation of systemic inflammatory response and coagulation together

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::74041dd760df2f84c4a90a403cef7641
https://pubmed.ncbi.nlm.nih.gov/20221873

Zobrazit plný text záznamu

Preface

Autor: Charles Bisgaier

Publikováno v: Current Medicinal Chemistry-Immunology, Endocrine & Metabolic Agents. 1:i-i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27a8c7f29aaebb9fab8c8cabe33b5854
https://doi.org/10.2174/1568013013359122

Zobrazit plný text záznamu

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients

Autor: Rebecca Bakker-Arkema, Michael J. Koren, Charles Bisgaier, Harold E. Bays, Evan A. Stein

Publikováno v: Journal of Clinical Lipidology. (5):1212-1222

BackgroundEzetimibe added to statin therapy further reduces LDL-C and clinical atherosclerotic cardiovascular disease compared to statin alone. However, the number of effective and safe oral agents for patients not at LDL-C goal is limited. In prior

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6edac5f6dd9aa824b8c19c1aadbe9d37

Zobrazit plný text záznamu